Literature DB >> 20573374

Interobserver variability in the evaluation of mismatch repair protein immunostaining.

Louise Klarskov1, Steen Ladelund, Susanne Holck, Karina Roenlund, Jan Lindebjerg, Jacob Elebro, Britta Halvarsson, Jenny von Salomé, Inge Bernstein, Mef Nilbert.   

Abstract

Immunohistochemical staining for mismatch repair proteins has during recent years been established as a routine analysis in many pathology laboratories with the aim to identify tumors linked to the hereditary nonpolyposis colorectal cancer syndrome. Despite widespread application, data on reliability are lacking. We therefore evaluated interobserver variability among 6 pathologists, 3 experienced gastrointestinal pathologists and 3 residents. In total, 225 immunohistochemically stained colorectal cancers were evaluated as having normal, weak, loss of, or nonevaluable mismatch repair protein staining. Full consensus was achieved in 51% of the stainings for MLH1, 61% for PMS2, 83% for MSH2, and 45% for MSH6. Weak stainings were the main cause of reduced consensus, whereas contradictory evaluations with normal as well as loss of staining were reported in 2% to 6% of the tumors. Interobserver variability was considerable, though experienced pathologists and residents reached the same level of consensus. Because results from immunohistochemical mismatch repair protein stainings are used for decisions on mutation analysis and as an aid in the interpretation of gene variants of unknown significance in hereditary nonpolyposis colorectal cancer, the interobserver variability identified highlights the need for quality assessment programs, including guidelines for classification of different expression patterns.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573374     DOI: 10.1016/j.humpath.2010.03.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).

Authors:  Thomas G Papathomas; Lindsey Oudijk; Alexandre Persu; Anthony J Gill; Francien van Nederveen; Arthur S Tischler; Frédérique Tissier; Marco Volante; Xavier Matias-Guiu; Marcel Smid; Judith Favier; Elena Rapizzi; Rosella Libe; Maria Currás-Freixes; Selda Aydin; Thanh Huynh; Urs Lichtenauer; Anouk van Berkel; Letizia Canu; Rita Domingues; Roderick J Clifton-Bligh; Magdalena Bialas; Miikka Vikkula; Gustavo Baretton; Mauro Papotti; Gabriella Nesi; Cécile Badoual; Karel Pacak; Graeme Eisenhofer; Henri J Timmers; Felix Beuschlein; Jérôme Bertherat; Massimo Mannelli; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo; Winand Nm Dinjens; Esther Korpershoek; Ronald R de Krijger
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

Review 2.  History, genetics, and strategies for cancer prevention in Lynch syndrome.

Authors:  Fay Kastrinos; Elena M Stoffel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

Review 3.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

4.  Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.

Authors:  Fay Kastrinos; Ewout W Steyerberg; Judith Balmaña; Rowena Mercado; Steven Gallinger; Robert Haile; Graham Casey; John L Hopper; Loic LeMarchand; Noralane M Lindor; Polly A Newcomb; Stephen N Thibodeau; Sapna Syngal
Journal:  Gut       Date:  2012-02-16       Impact factor: 23.059

5.  Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence.

Authors:  Kyung-Hwa Lee; Ji-Shin Lee; Jong-Hee Nam; Chan Choi; Min-Cheol Lee; Chang-Soo Park; Sang-Woo Juhng; Jae-Hyuk Lee
Journal:  Langenbecks Arch Surg       Date:  2011-06-25       Impact factor: 3.445

Review 6.  Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review.

Authors:  Alexander M Metcalf; Amanda B Spurdle
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

7.  A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer.

Authors:  Xiaohui Zhao; Dongfang Dai; Xiaoqin Li; Bo Shen; Xiaofeng Chen; Yongqian Shu; Deqiang Wang
Journal:  Gastric Cancer       Date:  2019-04-15       Impact factor: 7.370

8.  Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome.

Authors:  Wei Chen; Heather Hampel; Rachel Pearlman; Dan Jones; Weiqiang Zhao; Mohammed Alsomali; Deborah Knight; Wendy L Frankel
Journal:  Hum Pathol       Date:  2020-07-08       Impact factor: 3.466

9.  Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Authors:  Elizabeth C Smyth; Andrew Wotherspoon; Clare Peckitt; David Gonzalez; Sanna Hulkki-Wilson; Zakaria Eltahir; Matteo Fassan; Massimo Rugge; Nicola Valeri; Alicia Okines; Madeleine Hewish; William Allum; Sally Stenning; Matthew Nankivell; Ruth Langley; David Cunningham
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 33.006

10.  Germline and Tumor Sequencing as a Diagnostic Tool To Resolve Suspected Lynch Syndrome.

Authors:  Bernard J Pope; Mark Clendenning; Christophe Rosty; Khalid Mahmood; Peter Georgeson; Jihoon E Joo; Romy Walker; Ryan A Hutchinson; Harindra Jayasekara; Sharelle Joseland; Julia Como; Susan Preston; Amanda B Spurdle; Finlay A Macrae; Aung K Win; John L Hopper; Mark A Jenkins; Ingrid M Winship; Daniel D Buchanan
Journal:  J Mol Diagn       Date:  2020-12-29       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.